Top 50 Medical VC Funds & Investors in China (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
BioVenture
VC Fund
|
38 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.9M–$73M |
|
HSG
VC Fund
|
34 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Qiming Venture Partners
VC Fund
|
31 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$142M |
|
Med-Fine Capital
VC Fund
|
27 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Legend Capital
VC Fund
|
24 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.8M–$200M |
|
Frees Fund
VC Fund
|
20 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
Marathon Venture Partners
VC Fund
|
20 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$462M |
|
Cowin Venture
VC Fund
|
20 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
20 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$142M |
|
Puhua Capital
VC Fund
|
19 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.4M–$100M |
|
Lilly Asia Ventures
VC Fund
|
18 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$259M |
|
IDG Capital
VC Fund
|
17 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$200M |
|
Matrix Partners China
VC Fund
|
16 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.4M–$108M |
|
Highlight Capital
VC Fund
|
16 | China, United States, Portugal | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$73M |
|
Prox Ventures
VC Fund
|
16 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Dalton Venture
VC Fund
|
15 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $450k–$47M |
|
Legend Star
VC Fund
|
15 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Biotechnology | $425k–$52M |
|
Northern Light Venture Capital
VC Fund
|
15 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$100M |
|
BioTrack Capital
VC Fund
|
15 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $3M–$168M |
|
ZSVC
VC Fund
|
15 | China, United States, India | Series A, Seed, Series B | Manufacturing, Medical, Health Care | $1.4M–$85M |
|
Share Capital
VC Fund
|
15 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$57M |
|
Haiyuan Capital
VC Fund
|
14 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $425k–$55M |
|
Cowin Capital
VC Fund
|
14 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$50M |
|
CDH Investments
VC Fund
|
14 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $7.3M–$300M |
|
Longpan Investment
VC Fund
|
13 | China, United States, Cayman Islands | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $14M–$60M |
|
Taiyu Investment
VC Fund
|
13 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.3M–$37M |
|
Shenzhen Capital Group
VC Fund
|
13 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.4M–$142M |
|
Sherpa Healthcare Partners
VC Fund
|
12 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.8M–$156M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
12 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $213k–$90M |
|
Cenova
VC Fund
|
12 | China, Singapore, United States | Series B, Series A, Series C | Medical, Health Care, Biotechnology | $1.4M–$100M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
11 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $2.8M–$145M |
|
Sunland Fund
VC Fund
|
11 | China | Series B, Series A, Seed | Medical, Health Care, Medical Device | $1.4M–$28M |
|
Shunwei Capital
VC Fund
|
10 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$130M |
|
Long Hill Capital
VC Fund
|
10 | China, United States | Series A, Series B, Series C | Medical, Health Care, Training | $1.8M–$100M |
|
EFung Capital
VC Fund
|
10 | China, United States, India | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $1.4M–$87M |
|
Pan-Lin Capital
VC Fund
|
10 | China, United States, Canada | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $1k–$57M |
|
Trustbridge Partners
VC Fund
|
9 | China, United States, United Kingdom | Series A, Series B, Series C | Education, Health Care, Medical | $1.4M–$100M |
|
Lotus Lake Ventures
VC Fund
|
9 | China, India | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $42k–$99M |
|
Green Pine Capital Partners
VC Fund
|
9 | China, United States, Canada | Series A, Series B, Angel | Software, Biotechnology, Manufacturing | $425k–$150M |
|
Kaitai Capital
VC Fund
|
9 | China, United States, Singapore | Series A, Series B, Angel | Biotechnology, Health Care, Pharmaceutical | $425k–$57M |
|
Gaorong Capital
VC Fund
|
9 | China, United States, Hong Kong | Series A, Series B, Seed | Information Technology, Software, Artificial Intelligence | $2.8M–$110M |
|
CD Capital
VC Fund
|
9 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Hillhouse Investment
VC Fund
|
9 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Software | $2.9M–$230M |
|
Addor Capital
VC Fund
|
9 | China, Hong Kong, Singapore | Series A, Series B | Manufacturing, Semiconductor, Electronics | $1.4M–$43M |
|
Fortune Venture Capital
VC Fund
|
9 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $425k–$73M |
|
BIOCHING CAPITAL
VC Fund
|
9 | China | Angel, Series A, Seed | Medical, Medical Device, Biotechnology | $425k–$100M |
|
Huagai Capital
VC Fund
|
9 | China, United States, Germany | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$90M |
|
Haibang Capital
VC Fund
|
9 | China | Series A, Angel, Series B | Health Care, Biotechnology, Manufacturing | $425k–$71M |
|
Oriental Fortune Capital
VC Fund
|
8 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
SBCVC
VC Fund
|
8 | China, United States, Australia | Series B, Series A, Series C | Health Care, Software, Medical | $2M–$100M |
| Access all 2613 VC funds in China Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 165
- Round size: Seed $7.1M–$20M; Series A $1.9M–$43M; Series B $3M–$73M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Jiamuyao Medical — Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
- Xingyuanzhi Robotics — Xingyuanzhi Robotics strives to develop multimodal spatial intelligence systems and a universal embodied brain capable of comprehending and interacting with the physical world.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 740
- Round size: Series A $5M–$64M; Series B $10M–$100M; Series C $15M–$142M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Plum — Plum is an e-commerce platform for second-hand fashion products. It works as a one-stop consignment service platform that provides filming, sales, customer service, sale, and a full set of consignment services. Plum was founded on 2015 and is headquartered in Beijing, China.
- Bytelumio — Bytelumio creates advanced all-optical networks that deliver high-speed connections of 800G and 1.6T for data centers.
- Guangjing Energy — Guangjing Energy is a perovskite solar cell module developer, dedicated to the R&D of long-life large-area perovskite solar cell modules.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 78
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
- Rebbeca Med — Rebecca is committed to the application of precision-controlled MEMS radio frequency technology in clinical disease control and rehabilitation. Its core technology comes from the core team's many years of experience and achievements in research and development and productization at the University of California, Fortune 500 medical equipment,and electronic equipment companies. The company cooperated with domestic university research institutes and many top three hospitals in Beijing, Shanghai, and Hangzhou to independently develop micro-radio frequency technology that surpassed similar products in Europe and America. It focuses on delivering innovative medical solutions to the hands of professional caregivers. Rebecca's team possesses technical expertise in micro-devices, RF, and device integration through years of field practice in micro-electronics and clinical innovation.
- BV Laser — BV Laser is a manufacturer of medical beauty equipment.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 388
- Round size: Series A $2.8M–$94M; Series B $12M–$113M; Series C $14M–$200M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- ESWIN Computing — ESWIN Computing provides research and development of RISC-V computing architecture.
- Yosemite Clinic — Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitationmedicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 198
- Round size: Seed $1.4M–$14M; Angel $425k–$17M; Series A $1.4M–$35M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Neurodome — Neurodome is a manufacturer of non-invasive deep brain nerve modulation technology. It focuses on the research and development of non-invasive deep brain nerve modulation products.
- Pulin Technology — Pulin Technology provides tools and materials for creating nanoimprints and contributes to the study and advancement of fundamental technologies.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$28M; Series B $14M–$462M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 97
- Round size: Angel $425k–$1.4M; Series A $1.4M–$28M; Series B $2.8M–$257M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Furong Biotech — Furong Bio is a developer of innovative tumor immunology drugs.
- Amador Bioscience — At Amador we provide global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
- BioTroy Therapeutics — BioTroy Therapeutics is engaged in tumor immunity and is used for multi-omics tumor analysis, receptor-ligand discovery, research on target signal transduction pathways, antibody discovery and engineering, drug efficacy and large animal translational medicine, biomarkers, and precision medicine.
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $8M–$50M; Series A $10M–$36M; Series B $14M–$142M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Haimai Medical — Haimai Medical is a platform for tissue engineering and regenerative medicine technology. It focused on the development and manufacture of allogeneic small-caliber tissue-engineered blood vessels suitable for the establishment of chronic renal failure dialysis vascular access, lower extremity arterial trauma blood vessel replacement, lowerextremity atherosclerosis, and coronary heart disease bypass surgery.
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
- Spectrum-Dynamics — attenuation correction, deep learning, stress test, CTLC, Nuclear Medicine, Digital SPECT, CZT
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 200
- Round size: Seed $1.4M–$29M; Series A $1.4M–$41M; Series B $2.8M–$100M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- DeepWay — DeepWay is a maker and developer of intelligent electric commercial vehicles.
- Matridx — Matridx focuses on molecular diagnostic technology for infectious pathogens. Matridx uses the leading diagnostic technology to promote the changes in the diagnosis of infectious diseases, to make the diagnosis more simple, more rapid, and more intelligent.
- Yitang Technology — Yitang Technology is a developer specializing in high-speed and high-precision placement machines. The company is dedicated to the research and development (R&D) of these advanced machines, as well as the industrialization of intelligent production line solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 212
- Round size: Series A $14M–$100M; Series B $25M–$112M; Series C $28M–$259M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
- Alebund Pharmaceuticals — Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 725
- Round size: Series A $3M–$112M; Series B $7.4M–$142M; Series C $15M–$200M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- RootCloud — ROOTCLOUD is an IIoT platform provider, which has created IIoT platforms that have satisfied the needs of customers worldwide.
- Yuanfudao — Founded in 2012, Yuanfudao is the largest online live courseplatform servicing primary and secondary school students in China. With a paying userbase of over 1 million, Yuanfudao offers a comprehensive curriculum spanning fromprimary school English, Mathematical Olympiad to all-subject courses in secondaryschool. Its unique online feature and largepool of quality teachers enable students toaccess live online tutoring at home taught by national renowned teachers, benefitinghundreds of thousands of students across the country.
- Bodor Laser — Bodor Laser is a manufacturing company engaged in the R&D, production, and marketing of laser cutting machines. The company's laser products are high powered and range from 25000W, 30000W, 40000W, and 22000W laser cutting machines. The company is also the highest ranked in 10kW+ laser cutting machine sales volume.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 440
- Round size: Seed $1.4M–$32M; Series A $2.8M–$60M; Series B $9.5M–$108M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Ambilight — Ambilight focuses on smart and flexible thin-film innovation and manufacturing. The company has multiple international leading technologies, ranging from material synthesis, manufacturing to product design. Two innovation centers, located in Shenzhen and the US, are working strategically with multiple Fortune Global 500 companies.
- Ucello Therapeutics — Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Portugal
Investor stats
- Total investments: 154
- Round size: Seed $8.5M–$73M; Series A $2.8M–$73M; Series B $7.6M–$70M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Yixiu — Yixiu provides sleep health products such as smart wearables, smart home sleep scene hardware, sleep data analysis platforms, energy management apps, and more.
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 76
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- DotBio — DotBio is a biopharmaceutical company specialized in next-generation domain antibody therapies.
- Coastar Therapeutics — Coastar Therapeutics develops an erythrocyte enveloped virus delivery technology platform to perform repeated virus dosing. It evades recognition and attack by the immune system to address the challenges of systemic and repeated administration of drug therapies. Coastar's process technology and “red blood cell membranes only” enable thecompany to overcome the challenges of mass production and standardization, and has cost advantages. The company's first product targets oncolytic viruses and is developing ELCV solutions for other therapies.The company was founded in 2017 and is based in San Diego, CAlifornia.
- Leadinno Medical Valley — Leadino Medical Valley is a producer of medical devices for neuroregulatory functions.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 132
- Round size: Seed $450k–$5M; Series A $2.8M–$17M; Series B $2.8M–$47M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- MacroLux — MacroLux Medical Technology Co., Ltd.
- Kangyuan Medical — Kangyuan Medical is committed to developing, and manufacturing a new generation of precise and effective blood purification adsorption materials.
- MaiKeWei Medical — MaiKeWei Medical is a national high-tech company. It has an entire system that includes production, sales, and R&D.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 137
- Round size: Seed $1.4M–$19M; Angel $425k–$7.1M; Series A $1.4M–$52M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — raised $109M in 2018
Portfolio highlights
- LyncBio Therapeutics —
- Beijing Anton Fusion — Beijing Anton Fusion is an innovative company that specializes in commercial power production technologies.
- Booster Robotics — Accelerating Evolution is a humanoid robotics company. It provides humanoid robots to AI firms and research institutes, as well as quick mass production and supply of standard items.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 242
- Round size: Seed $1.3M–$100M; Series A $4.3M–$40M; Series B $11M–$62M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- VOC AI — VOC AI offers AI tools for ecommerce insights and customer service solutions.
- Wanglitong — Wanglitong manufactures lithium battery auxiliary materials. It currently specializes on lithium battery films and membrane materials. Its current product lines include brown high-temperature tape, milky white OPP tape, and TPU expansion tape, all of which have reached mass production.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 84
- Round size: Seed $14M–$168M; Series A $3M–$43M; Series B $14M–$150M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- PrinoPharma — PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets.
- Shenluo Medical — Shenluo Medical manufactures functional neural implantable medical devices.
- LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
ZSVC is a Chinese venture capital firm specialized in seed and early stage investments.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, India
Investor stats
- Total investments: 137
- Round size: Seed $1.4M–$4M; Series A $1.4M–$16M; Series B $2.8M–$85M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Zhicheng AI — Zhicheng AI is a developer of general-purpose artificial intelligence robots, dedicated to designing and building intelligent robotic systems that integrate advanced AI algorithms, perception technologies, and adaptive learning capabilities
- Ounuo Semiconductor — Ounuo Semiconductor is a manufacturing company that provides research and development of semiconductor equipment.
- Sunseeker — Sunseeker Power Equipment specializes in the manufacturing and supplying of garden tools, focusing on innovation in the realm of outdoor power equipment. The product range includes robotic lawn mowers, cordless Li-ion battery-powered tools, and petrol-powered equipment, catering to both garden and agricultural needs. The brand emphasizes onproviding solutions that enhance efficiency and ease of use in maintaining outdoor spaces. Sunseeker Power Equipment's offerings are designed to meet the demands of a global market, with a significant emphasis on exporting their products under the brand name 'SUNSEEKER 山科'. The company's portfolio extends to engines and a variety of garden tools series, showcasing a commitment to diversifying and expanding its product lineup to address the evolving needs of its customers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 64
- Round size: Seed $1.4M–$14M; Angel $425k–$14M; Series A $1.4M–$55M
- Lead/follow: 53% lead, 47% follow
Portfolio highlights
- Tianyuanxing — Tianyuanxing is a general industrial embodied intelligent platform developer whose primary focus is on the research and development of the "TX01" wheeled chassis humanoid dual-arm robot.
- Anxin Medical — Anxin Medical is a company dedicated to the research, development, production, and sales of innovative medical devices. The company focuses on advancing healthcare technology through continuous innovation, integrating cutting-edge science and engineering to create high-quality, reliable, and efficient medical products.
- Hangzhou Atom — Hangzhou Atom focuses on the R&D of atomic-level high-end materials manufacturing equipment, specializing in vacuum chemical vapor deposition
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 281
- Round size: Seed $1.4M–$20M; Series A $4.3M–$43M; Series B $2.8M–$50M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Cosminde — Cosminde is a developer of gastroenterology soft electronic endoscope products.
- AVIC Robots — AVIC is an emerging high-tech company specialising in artificial intelligence and service robots.
- Moment Control Xinchen — Moment Control Xinchen is a manufacturer of technologically advanced industrial control systems.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 272
- Round size: Series A $7.3M–$198M; Series B $14M–$142M; Series C $14M–$300M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Spear Bio — Successive Proximity Extension Amplification Reaction (SPEAR) technology from Spear Bio enables ultra-sensitive biomarker detection using ultra-small samples.
- Vision Medicals — Vision Medicals is a provider of pathogenic gene diagnostic services, focusing on infection-precise medical treatment, high-throughput sequencing-based pathogen metagenomics and CRISPR-based rapid diagnosis and other new technologies, effectively improving the detection ability of clinical pathogens and shortening The reporting cycle acceleratedthe development of the infection-accurate medical industry. The company developed a pathogenic nucleic acid enrichment technology with independent intellectual property rights for the detection of pathogenic micronucleic acids in clinical samples. The pathogen macro was established through the accumulation of pathogen detection big data. Genomics intelligent analysis and reporting system.
- ReviR Therapeutics — ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 32
- Round size: Seed $14M–$60M; Series A $14M–$28M; Series B $14M–$37M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Maibozhixing —
- Baiyi Pharmaceutical — Baiyi Pharmaceutical is a research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for neurological diseases, aiming to address unmet medical needs and improve patient outcomes.
- BioTroy Therapeutics — BioTroy Therapeutics is engaged in tumor immunity and is used for multi-omics tumor analysis, receptor-ligand discovery, research on target signal transduction pathways, antibody discovery and engineering, drug efficacy and large animal translational medicine, biomarkers, and precision medicine.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 28
- Round size: Seed $4.3M–$7.4M; Series A $14M–$37M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Yili Pharmaceutical — Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 405
- Round size: Series A $1.4M–$142M; Series B $13M–$142M; Series C $4.3M–$142M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 99
- Round size: Series A $2.8M–$50M; Series B $14M–$100M; Series C $12M–$156M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
- Biortus — Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 141
- Round size: Seed $213k–$14M; Angel $425k–$14M; Series A $1.4M–$90M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- DreamTech — DreamTech is an AI startup company focusing on native 3D generation.
- Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
- GeneQuantum Healthcare — GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumorAntibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline.
Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, Singapore, United States
Investor stats
- Total investments: 44
- Round size: Series A $1.4M–$14M; Series B $13M–$61M; Series C $15M–$100M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Phage Pharm — Phage Pharm is a professional enterprise in the industrialization of bacteriophages.
- Accro Bioscience — Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis.
- BRC Biotechnology — BRC Biotechnology specializes in quality testing services for biopharmaceutical compliance. BRC Biotechnology supports biological agents, quality evaluation of biopharmaceutical goods such as cell gene therapy, nucleic acid medications, and vaccines.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 227
- Round size: Seed $7M–$65M; Series A $2.8M–$73M; Series B $5.5M–$145M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Nyonic — Nyonic develops breakthrough AI technology to tackle difficult obstacles for businesses and is committed to developing a leading SOTA (state-of-the-art) basic model as well as an industry-leading, high-performance vertical model.
- Lanxin Computing — Lanxin Computing is a high-performance chip design company that focuses on the research and development of CPUs with RISC-V ecosystems.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Series B, Series A, Seed
- Geography: China
Investor stats
- Total investments: 31
- Round size: Seed $1.4M–$14M; Series A $1.4M–$14M; Series B $2.8M–$28M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Aopeng Yiliao — Aopeng Yiliao is a developer of vascular interventional surgery robots.
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 417
- Round size: Series A $1.4M–$41M; Series B $8.2M–$50M; Series C $20M–$130M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Hohem — Hohem is a world-leading brand dedicated to AI tracking gimbals for video shooting, providing consumer and professional stabilizers for smartphones and cameras.
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- Darma — DARMA - Digital Healt
Long Hill Capital is a next generation thesis-driven venture capital firm. We invest in technology-enabled healthcare and consumer services companies which seek to massively improve health and quality of life for every Chinese.Since 2005 the founding team of Long Hill Capital have led the China investing practice for New Enterprise Associates(NEA), a global investment firm with over $17 billion in committed capital. They are joined by an experienced team of investment and operations professionals from such firms as Matrix Partners China and Morningside VC. Together the Long Hill Capital team have over 30 years of China venture capital experience and over 15 years of senior operating experience at some of China’s most successful technology and healthcare companies including Alibaba, Huawei and Ping’an Good Doctor.Over the course of their venture capital careers, the Long Hill Capital team have invested in such industry leading companies as CITIC Pharmaceutical, WeDoctor, Hygeia Medical Services, GST Clinics, LineKong, LianLian Pay, Ele.Me, TheBeastShop and more.
Show more...Investment focus
- Industry: Medical, Health Care, Training
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 32
- Round size: Series A $1.8M–$14M; Series B $14M–$100M; Series C $28M–$60M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Qingyun Technology — Qingyun Technology is an artificial intelligence digital marketing platform company focusing on the pharmaceutical industry.
- Shengnuo Medical — Sono Medical is a biomedical technology company that focuses on R&D, design, production and sales of edical equipment in the field of cardiovascular diseases.
- Aibo Medical Robot — Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 68
- Round size: Series A $1.4M–$76M; Series B $14M–$87M; Series C $14M–$71M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
- Huiguan Biology — Huiguan Biology is a developer of super-resolution microscopes for in vivo drug screening.
- JGene Biotechnology — JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recentlyreceived angel round investment.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 73
- Round size: Seed $1k–$28M; Series A $1.4M–$35M; Series B $7.1M–$57M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Dishi Medical — Dishi Medical is a company that manufactures Ophthalmic Medical Devices and other micro-assisted robots supported by biotechnology.
- LyncBio Therapeutics —
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
Trustbridge Partners is a mission-driven growth equity firm founded in 2006 with approximately $8 billion under management.
Show more...Investment focus
- Industry: Education, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 110
- Round size: Series A $1.4M–$30M; Series B $15M–$100M; Series C $30M–$100M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Cherre — Connect all your real estate data and make it available to the entire organization for better investment, management, and underwriting decisions.
- Metafoodx — Metafoodx is on a mission to solve the challenge of food waste. We believe that it is one of the most critical factors for achieving global sustainability.
- Yuntongxun — Beijing Ronglian Yitong Information Technology Co., Ltd, established in 2009, is the first and also the largest open platform that provides full communication capability. Cloud communications by the professional communication capabilities packaged into API interface for web, desktop and mobile applications can easily embed calls, conferencing,call center, SMS /intelligent call, mobile IM functions.
Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech and high-tech enterprises with core competitiveness in the initial stage and growth stage..
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, India
Investor stats
- Total investments: 74
- Round size: Seed $42k–$14M; Series A $709k–$99M; Series B $2M–$40M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Zhiyu Veken —
- ICE Bioscience — ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection.
- Micro Interventional — Micro Interventional is a company that develops active interventional innovative medical devices. It emphasizes the development of novel medical devices with a product strategy centered on the precise interventional treatment of coronary heart disease and peripheral arterial disease.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Software, Biotechnology, Manufacturing
- Stage:Series A, Series B, Angel
- Geography: China, United States, Canada
Investor stats
- Total investments: 179
- Round size: Angel $425k–$2.9M; Series A $1.4M–$100M; Series B $9.9M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- MindRank AI — MindRank AI is a developer of proprietary end-to-end AI-driven drug discovery platform (Molecule Pro™).
- Sungen Biomedical — Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 123
- Round size: Angel $425k–$14M; Series A $1.4M–$35M; Series B $4.3M–$57M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Primelink Bio — Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.
- Huaboron Neutron — Huaboron Neutron is a biotechnology company that develops boron drugs and boron neutron capture therapy devices for the diagnosis of malignant cancers.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 260
- Round size: Seed $2.8M–$57M; Series A $2.8M–$73M; Series B $14M–$110M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2020
Portfolio highlights
- AIpark — AIpark is provides a smart parking management solution. AIPark upgrades traditional parking spaces into “smarter ones” for local governments or businesses by leveraging on its in-house visual recognition technologies.
- XYZ Robotics — XYZ Robotics develops AI-enabled robotic perception and manipulation technology for logistics and manufacturing automation. The company develops autonomous robotic solutions for put wall sorting and goods-to-person picking. Its robot sorts unorganized, random warehouse goods into groups of customer orders. The solution embodies its strength in deeplearning and robotics.
- Danke Apartment — Danke Apartment (蛋壳公寓) is a leading internet enabled apartment management startup in China. Founded in Jan 2015, Danke is managing over 320K apartment units in Beijing, Shanghai, Shenzhen, Hangzhou, etc
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 69
- Round size: Seed $1.4M–$14M; Series A $1.4M–$32M; Series B $7.1M–$34M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Pipi Bear —
- Senas Medical — Senas Medical focuses on innovative cardiac electrophysiology solutions.
- Greenon Biotech — Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 331
- Round size: Series A $2.9M–$142M; Series B $14M–$230M; Series C $15M–$220M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $11B in 2018
Portfolio highlights
- Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
- Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 297
- Round size: Series A $1.4M–$28M; Series B $11M–$43M
- Lead/follow: 51% lead, 49% follow
Portfolio highlights
- Eighteeth — Eighteeth focuses on the research and production of dental instruments. Eighteeth has 14 product categories including endo motor, apex locator, ultrasonic scaler, curing light, X-Ray unit, intraoral sensor, intraoral scanner, and owns 110 authorized patents.
- Fengtai Technology — Focusing on industrial information security, Fujian and Taiwan technology mainly provides professional, standard chemical control safety consulting and evaluation services to ensure information security of key industrial information infrastructure and improve security protection solutions. It mainly serves the government, industry customers, designinstitutes, research institutes, institutes, integrators and hardware and software manufacturers. Through visual, process and customized tools and methods, it helps users to carry out effective risk management and reliable operational support. .
- Mingjian Electronics — Mingjian Electronics is a radio frequency test equipment research and development firm as well as a national high-tech enterprise specializing in radio frequency test equipment.
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 254
- Round size: Seed $425k–$73M; Series A $1.4M–$41M; Series B $2.8M–$56M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $780M in 2021
Portfolio highlights
- Dishi Medical — Dishi Medical is a company that manufactures Ophthalmic Medical Devices and other micro-assisted robots supported by biotechnology.
- ELITE Technology — Elite's seven-axis collaborative robot uses the latest deep neural network (DNN) technology to identify irregularly shaped objects and accurately capture them. Through the fusion of 2D and 3D data, the accuracy requirements of the depth vision sensor are reduced, the success rate of the capture is improved, the versatility of the grabbingsystem is enhanced, and the hybrid object capture is supported. The system can be widely used in 3C, logistics, retail, catering and other industries.
- Meiwei Dental Group — Meiwei Dental Medical Group is affiliated to Tianyi Group and is committed to opening up the overall health management of the whole people from the prevention, opening up to create the “China's first platform for oral medicine”, and through strategic investment, standard output, medical technology improvement and brand management as excellentin China. Oral medical brands and experts empower and achieve personalized development, and jointly promote the rapid development of the private dental health industry. Meiwei Dental cooperates with DNV GL, an internationally recognized certification body, to establish the first internationally-advanced dental clinic management system and medical standard “M+” management certification, and empowers partners through the construction of “five-one-one license”. Achieve scientific research and innovation and talent cultivation academicization, based on SaaS cloud platform informationization, medical and therapeutic environment comfort, medical service specialization, consumables and equipment refinement. Through the introduction of the "business partner" mechanism, the company has created a "stable and win-win" community of destiny, with the principle of complementarity and mutual integration, and the cooperation of partners in the medical capital, talent, technology, market, management and other dimensions. Carry out all-round empowerment. At present, Meiwei has invested in the acquisition of Weile Dental, Xinqiao Oral, Zhongshan Oral, DUANG DUANG Children's Oral, Meier Oral, Love Tooth, Hanmei Oral, Zhimei Dental, Tsinghua Sunshine Oral, Houcheng Oral, Hengmei Oral, Small The White Rabbit has a total of 12 dental chain brands covering 35 cities and 130 dental hospitals and clinics.
BIOCHING CAPITAL is an investment management firm.
Show more...Investment focus
- Industry: Medical, Medical Device, Biotechnology
- Stage:Angel, Series A, Seed
- Geography: China
Investor stats
- Total investments: 20
- Round size: Angel $425k–$100M; Series A $14M–$14M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Lunke Medical — Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry.
- Taose Tuantuan — Taose Tuantua is a sex toy company that primarily offers TAOSETT sex toy academy and exquisite sex toy community store services.
- Qinglan Jichuang — Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Germany
Investor stats
- Total investments: 133
- Round size: Angel $425k–$15M; Series A $1.4M–$63M; Series B $3.5M–$90M
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- Baijun Biotech — Baijun Biotechnology is a major player in the field of biopharmaceutical R&D services due to its one-stop biotechnology R&D service platform, strong R&D skills, and extensive industry experience.
- GenFleet Therapeutics — GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize thebody's own immune system.
- MicuRx Pharmaceuticals — MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available inChina. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Angel, Series B
- Geography: China
Investor stats
- Total investments: 43
- Round size: Angel $425k–$2.8M; Series A $1.4M–$14M; Series B $10M–$71M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- XPTC — XPTC is a wafer slicing equipment developer, dedicated to the research, development, production, and sales of ultra-precision thinning cutting equipment and related consumables.
- Wuwen Zhike — Wuwen Zhixing is an intelligent driving service provider dedicated to offering professional and cutting-edge integrated solutions for AI data and simulation verification, as well as developing AI data infrastructure and accelerators.
- SynRx Therapeutics — Sanctuary Bio is a DNA damage repair drug developer, focusing on the field of DNA damage repair.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 232
- Round size: Seed $2.9M–$73M; Series A $1.4M–$30M; Series B $2.9M–$100M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
- Technological Innovation — Technological Innovation is a provider of brain-computer interface (BCI) technology research and development, as well as application services.
- Photoacoustic Pharmaceuticals — Photoacoustic Pharmaceuticals is an innovative developer of photosensitizers and related products. It is committed to advancing the development of dynamic photoacoustic therapy.
Established in 2000, SB China Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Their investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and they invest across all stages of companies.Withextensive entrepreneurial and operating experiences, their professional and seasoned deal team members recognize the vision and champion the ideas of start-up companies. In addition to providing capital support, they help their portfolio companies realize their strategic and commercial potential by giving value-adding services and advices including planning, business development, recruiting and resources deployment.They have a proven track record and solid reputation in identifying high potential start-ups and creating successful industry-leading companies. Some of their spotlight portfolio companies are Alibaba, Taobao, Focus Media, GDS, BGI, Ankon, Di’an, and Edan.With their operational headquarters located in Shanghai and regional offices spread in Beijing, Shenzhen, Chengdu, Hangzhou and Taiwan, they have an extensive coverage of the greater China region and access to potential investment opportunities.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Australia
Investor stats
- Total investments: 127
- Round size: Series A $2M–$28M; Series B $4.5M–$43M; Series C $10M–$100M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- UCaize — UCaize is a biopharmaceutical company that researches and develops novel medications for the treatment of blood cancers.
- Cowarobot — The purpose of establishing COWAROBOT is to bring people the future travel experience by using robotics, self-driving technology and other intelligent solutions. COWAROBOT commits to solving the difficulties and pain points during traveling so as to bring convenience and pleasure to all people who are on the move.
- Shengyin Optoelectronics — Shengyin Optoelectronics is a platform-based micro-nano manufacturing firm that creates ornamental films for electrical appliances and portable electronics.
Medical VC funding in China at a glance
Stats across 2.6k deals from 2.6k investors.
Access all 2613 VC funds in China Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 2613 VC funds investing in China Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!